Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis
<p>
<b>
Objective
</b>
To determine the effect of fibre, antispasmodics,<sup> </sup>and peppermint oil in the treatment of irritable bowel syndrome.<sup> </sup>
</p>
<p><sup></sup> </p>
<p><b>Review methods</b> Randomised controlled trials comparing fibre,<sup> </sup>antispasmodics, and peppermint oil with placebo or no treatment<sup> </sup>in adults with irritable bowel syndrome were eligible for inclusion.<sup> </sup>The minimum duration of therapy considered was one week, and<sup> </sup>studies had to report either a global assessment of cure or<sup> </sup>improvement in symptoms, or cure of or improvement in abdominal<sup> </sup>pain, after treatment. A random effects model was used to pool<sup> </sup>data on symptoms, and the effect of therapy compared with placebo<sup> </sup>or no treatment was reported as the relative risk (95% confidence<sup> </sup>interval) of symptoms persisting.<sup> </sup></p>
<p><b>Results</b> 12 studies compared fibre with placebo or no treatment<sup> </sup>in 591 patients (relative risk of persistent symptoms 0.87,<sup> </sup>95% confidence interval 0.76 to 1.00). This effect was limited<sup> </sup>to ispaghula (0.78, 0.63 to 0.96). Twenty two trials compared<sup> </sup>antispasmodics with placebo in 1778 patients (0.68, 0.57 to<sup> </sup>0.81). Various antispasmodics were studied, but otilonium (four<sup> </sup>trials, 435 patients, relative risk of persistent symptoms 0.55,<sup> </sup>0.31 to 0.97) and hyoscine (three trials, 426 patients, 0.63,<sup> </sup>0.51 to 0.78) showed consistent evidence of efficacy. Four trials<sup> </sup>compared peppermint oil with placebo in 392 patients (0.43,<sup> </sup>0.32 to 0.59).<sup> </sup></p>
<p><b>Conclusion</b> Fibre, antispasmodics, and peppermint oil were all<sup> </sup>more effective than placebo in the treatment of irritable bowel<sup> </sup>syndrome.<sup> </sup></p>
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。